President and Chief Executive Officer
Will Lewis joined Insmed in September 2012 as President and Chief Executive Officer and as a member of the Board of Directors. Will is the former Co-Founder, President and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR). Prior to Aegerion, Will spent more than 10 years working in the US and Europe in investment banking for JP Morgan, Robertson Stephens and Wells Fargo. Will serves on the Boards of UniQure and Oberlin College. Will holds a Bachelor of Arts degree cum laude from Oberlin College, a Master of Business Administration from Case Western Reserve University and a Juris Doctor with Honors from Case Western Reserve University. Prior to attending graduate school he worked in the Foreign Service for the US Government.
General Counsel & Corporate Secretary
Christine Pellizzari joined Insmed in July 2013. She brings nearly 20 years of senior-level leadership experience in the global biotechnology and pharmaceutical industry. Most recently, Christine served as Executive Vice President, General Counsel and Secretary of Aegerion Pharmaceuticals, Inc., a publicly traded company developing therapies for rare diseases. Among her accomplishments and responsibilities at Aegerion, Christine oversaw all the legal aspects of that company’s successful IPO and secondary public offering and served as a member of the Executive Management Committee. Prior to joining Aegerion, Christine served as Senior Vice President, General Counsel and Secretary of Dendrite International, Inc., a publicly traded company that provided sales effectiveness, promotional and compliance solutions to the global pharmaceutical industry. She was a member of the company’s Executive Operations Management Committee and helped lead many critical initiatives during her 9-year tenure, including the sale of the company to Cegedim S.A. in May 2007. Christine joined Dendrite from the law firm of Wilentz, Goldman & Spitzer where she specialized in health care transactions and related regulatory matters. Before joining Wilentz, Christine served as law clerk to the Honorable Reginald Stanton, Assignment Judge for the Superior Court of New Jersey. Christine received her BA, cum laude, from the University of Massachusetts, Amherst and her JD from the University of Colorado, Boulder.
Walter Perkins, PhD
Chief Technology Officer
Dr. Walter Perkins joined Insmed in December 2010 in connection with the business combination between Insmed and Transave. Prior to this, Walter joined Transave in 2002 and served as Chief Technology Officer. Walter has over 20 years’ experience utilizing lipid-based drug delivery systems and has authored over 66 scientific publications and patent applications. Prior to joining Transave, Walter spent 15 years with The Liposome Company (later a part of Elan Drug Delivery). At The Liposome Company, Walter was involved in the design of several lipid-based drug delivery systems, including an artificial lung surfactant formulation, and helped in the characterization, development and launch of the company’s two commercial products Abelcet® and Myocet®. As a part of Elan’s Drug Delivery Division, he played a lead role in the implementation of liposome technology in both inter-divisional projects and corporate partnerships. Walter received his bachelor’s and doctoral degrees in Biophysical Chemistry from the University of Virginia where he studied the physical and electrical properties of liposomal membranes.
Senior Vice President, Human Resources and Corporate Services
Nicole Schaeffer joined Insmed in October 2012. She brings more than 20 years of experience in Human Resources, organizational development, corporate operations and building life science organizations. Most recently Nicole served as Senior Vice President, Administration and Human Resources, for Amicus Therapeutics where she was responsible for the human resources, facilities and IT functions. While at Amicus, Nicole was responsible for the organizational growth and development of this high performing company from its earliest stages to its current position as a late-stage clinical company. During this time, she focused on developing a culture of excellence to support that growth. Prior to Amicus, she served as Senior Director, Human Resources, for three portfolio companies of Flagship Ventures, a venture capital firm, and in that capacity she managed human resources for three life sciences companies. She has also held HR leadership positions with Oak Industries and EMC Corporation. Nicole received her BA from the University of Rochester and her MBA from Boston University.
Eugene Sullivan, M.D.
Chief Medical and Scientific Officer
Dr. Eugene Sullivan joined Insmed in March 2015 as Chief Medical and Scientific Officer. Gene has more than 20 years of experience with a focus on pulmonary and orphan diseases. He is a medical doctor trained in internal medicine, pulmonary medicine and critical care medicine and practiced at the Cleveland Clinic from 1995 to 1999. From 1999 through 2006, Gene held several positions at the U.S. Food and Drug Administration, including Deputy Director of the Division of Pulmonary and Allergy Products. From 2007 through 2012, Gene was the Chief Medical Officer of United Therapeutics. In recent years, Gene was Vice President, Global Regulatory Affairs at AstraZeneca and consulted to companies, including Insmed, on clinical drug development and strategic regulatory matters. Gene graduated summa cum laude from the University of Maryland with a Bachelor of Science degree. He earned his medical degree from the University of Maryland, School of Medicine and conducted his internship and residency in Internal Medicine at the Medical College of Virginia. Gene completed his fellowship training in Pulmonary and Critical Care Medicine at the University of Colorado Health Sciences Center and received a Masters of Pulmonary Vascular Disease from the University of Bologna in Italy.
Senior Vice President, Corporate Development & Strategy
Wade Hampton King, MD, joined the company in March 2016 as Senior Vice President, Corporate Development and Strategy. Dr. King brings a unique scientific and financial background to Insmed that includes numerous leadership roles in business development, finance, management, and strategy at healthcare and investment companies. Dr. King began his career as a board certified anesthesiologist before joining the investment sector where he earned national recognition as a healthcare analyst. He holds a Bachelor of Arts degree, cum laude, from Princeton University; Doctor of Medicine and Master in Public Health degrees from University of North Carolina, Chapel Hill; and a Master of Science in Management degree from Stanford Graduate School of Business.
Chief Commercial Officer
Roger Adsett joined Insmed in September of 2016. Prior to joining Insmed, Roger held various leadership roles with Shire from 2005 to 2016. During his time as senior vice president of its gastrointestinal and internal medicine business unit, Roger oversaw global commercial P&L across six specialty and two rare disease brands within his BU. Previously, he served as Shire’s gastrointestinal business unit leader, responsible for building the a leading GI specialty business, including the leading global brand of mesalamine, Lialda®. Before joining Shire, Roger worked at AstraZeneca for 11 years, in a variety of commercial positions, including marketing director for the US launch of Nexium®, a medicine for the treatment of gastroesophageal reflux disease (GERD) and most recently serving as the global brand director for Symbicort®, a medicine for the treatment of asthma and chronic obstructive pulmonary disease. Prior to AstraZeneca, Roger spent three years at Accenture. Roger holds an M.B.A. from The Wharton School at the University of Pennsylvania and a B.A. in English and Economics from Bucknell University.